Human Imaging Core

人体成像核心

• 批准号: 9144762
• 负责人: BRADLEY J. ERICKSON
• 金额: $ 27.16万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9144762
• 关键词: Affect; Algorithms; Area; Atrophic; Automation; Autosomal Dominant Polycystic Kidney; Big Data; Biological Markers; Blood; Classification; Clinical Data; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Cyst; Cystic kidney; Data; Detection; Development; Diagnosis; Diffusion; Diffusion Magnetic Resonance Imaging; Disease; Disease Progression; End stage renal failure; Faculty; Foundations; Funding; Grant; Growth and Development function; Health Insurance Portability and Accountability Act; Hour; Human; Image; Image Analysis; Individual; Industry; International; Intracranial Aneurysm; Ischemia; Kidney; Kidney Calculi; Liver; Magnetic Resonance Elastography; Magnetic Resonance Imaging; Measurement; Measures; Methodology; Methods; Nephrons; Normal Range; Organ; Oxygen; Patients; Polycystic Kidney Diseases; Quality Control; Renal Blood Flow; Renal Tissue; Renal function; Research Personnel; Resources; Scanning; Secondary to; Services; Standardization; Surface; Techniques; Technology; Time; Tissues; Training; Translating; United States National Institutes of Health; X-Ray Computed Tomography; abstracting; analytical method; base; blood flow measurement; blood oxygen level dependent; calcification; clinical practice; cost; design; elastography; genomic data; imaging biomarker; imaging modality; improved; new technology; novel; outcome forecast; protocol development; rapid detection; therapy outcome; tool; urinary tract obstruction

HUMAN IMAGING CORE SUMMARY/ABSTRACT The focus of the Human Imaging Core (Director: Dr. Bradley Erickson) is to provide critical human imaging capabilities to MTPC investigators and extended national and international faculty by making a variety of services available. These include imaging protocol development; image transfer, management and storage; volumetric and other quantitative analysis (cyst distribution, cyst parenchyma-surface area, Dual energy CT) and advanced MR imaging analysis (renal blood flow measurements, intracranial aneurysm detection, and MR elastography) of affected organs in ADPKD. During the past grant cycle to date, the Human Imaging Core has provided image analysis for six NIH, two PKD Foundation, five industry, and three Mayo funded clinical studies or trials. These include volumetric analysis of 2,669 CT and 2,434 MR scans of kidneys or livers, in addition to MR measurements of RBF and other image analyses in a smaller number of patients. The volumetric analysis alone has taken approximately 5,613 hours. The Human Imaging Core has also assisted in the design and management of MR images from Mayo patients with ADPKD participating in multicenter clinical trials (CRISP and HALT) and the protocol development for DIPAK 1 (a clinical trial of Lanreotide supported by the Dutch Kidney Foundation and IPSEN Pharmaceutica). In addition, six new core services that were developed during the prior period: automated kidney segmentation from stereology, image-based classification of patients, magnetic resonance elastography, dual energy CT to characterize renal stones, renal blood flow, cyst- parenchyma surface area, are now available to researchers. Furthermore, the Human Imaging Core actively develops new technologies to enhance the breadth of offerings or the value of the current services. Technologies under development include: novel imaging methods for characterizing PKD (magnetization transfer imaging, diffusion, and blood-oxygen level determination) and differentiating cysts and parenchymal tissues. In addition to providing the services, the core offers training in these techniques. The core has educated and trained a large number of individuals from across the world on the proper use of tools to measure TKV and has also shared some of our algorithms developed in the past grant cycle. For these reasons, we believe that the Human Imaging Core is a critical resource for the study of PKD, and is a unique strength of the current application, as no other PKD Center has such a core.

人体成像核心摘要/摘要 人体成像核心（主任：Bradley Erickson 博士）的重点是提供关键的人体成像 通过各种方式向 MTPC 研究人员和扩展的国内和国际教师提供能力 可用的服务。其中包括成像协议开发；图像传输、管理和存储； 体积和其他定量分析（囊肿分布、囊肿实质表面积、双能 CT） 和先进的 MR 成像分析（肾血流测量、颅内动脉瘤检测和 MR ADPKD 受影响器官的弹性成像）。在迄今为止的过去资助周期中，人类成像核心已经 为六项 NIH、两项 PKD 基金会、五项行业和三项 Mayo 资助的临床研究提供图像分析 或试验。其中包括对 2,669 份 CT 扫描和 2,434 份肾脏或肝脏 MR 扫描进行体积分析，此外 对少数患者进行 RBF 的 MR 测量和其他图像分析。体积分析 仅此一项就花费了大约 5,613 小时。人类成像核心还协助设计和 参与多中心临床试验 (CRISP) 的 ADPKD Mayo 患者的 MR 图像管理 和 HALT）以及 DIPAK 1（由荷兰资助的兰瑞肽临床试验）的方案开发 肾脏基金会和 IPSEN Pharmaceutica）。此外，期间开发了六项新的核心服务 前期：体视学自动肾脏分割、基于图像的患者分类、 磁共振弹性成像、双能 CT 表征肾结石、肾血流、囊肿 薄壁组织表面积，现在可供研究人员使用。此外，人类成像核心积极 开发新技术以增强产品的广度或当前服务的价值。 正在开发的技术包括： 用于表征 PKD（磁化 转移成像、扩散和血氧水平测定）以及区分囊肿和实质 组织。除了提供服务之外，核心还提供这些技术的培训。核心有 对来自世界各地的大量个人进行了正确使用工具的教育和培训 测量 TKV 并分享了我们在过去的资助周期中开发的一些算法。对于这些 原因，我们相信人类成像核心是研究 PKD 的重要资源，并且是一个独特的资源。 当前应用程序的强度，因为没有其他 PKD 中心拥有这样的核心。